- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00103220
SJG-136 in Treating Patients With Advanced Solid Tumors
A Phase I Study With SJG-136 (NSC #694501) in Patients With an Advanced Solid Tumor
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To determine the toxicities, pharmacokinetic profile and the recommended phase 2 dose of SJG-136 in patients with an advanced solid tumor.
SECONDARY OBJECTIVES:
I. To determine preliminary efficacy data and evaluation of correlative markers of DNA damage and apoptosis in peripheral blood lymphocytes.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive SJG-136 intravenously (IV) over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Histologically confirmed solid tumor
- Advanced disease, defined as metastatic or unresectable disease
- Measurable indicator lesions
- Standard curative or palliative measures do not exist or are no longer effective
- Previously treated CNS metastases allowed provided patient has completed local therapy AND corticosteroids have been discontinued for at least 4 weeks
- No known leptomeningeal metastases
- Performance status - ECOG 0-2
- Performance status - Karnofsky 60-100%
- More than 3 months
- WBC ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin ≤ 1.0 mg/dL
- AST and ALT ≤ 2.5 times upper limit of normal
- Creatinine < 1.4 mg/dL
- No congestive heart failure
- No recent myocardial infarction
- No unstable angina
- No uncontrolled hypertension
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infection
- No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug
- No other significant medical history, unstable medical condition, or unstable systemic disease that would preclude study participation
- At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas and 8 weeks for UCN-01)
- At least 4 weeks since prior radiotherapy
- No prior radiotherapy to ≥ 25% of hematopoietic bone marrow
- Recovered from all prior therapy
- At least 4 weeks since prior investigational anticancer drugs
- No other concurrent investigational agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Treatment (SJG-136)
Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Givet IV
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Recommended phase 2 dose of SJG-136
Tidsram: Day 28
|
Defined as when ≤1 out of 6 patients achieve dose-limiting toxicity (DLT) at highest dose level below the maximally administered dose.
|
Day 28
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Naiyer Rizvi, Memorial Sloan Kettering Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NCI-2012-01462 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- U01CA069856 (U.S.S. NIH-anslag/kontrakt)
- MSKCC-04076
- CDR0000409581
- NCI-6818
- 04-076 (Memorial Sloan-Kettering Cancer Center)
- 6818 (CTEP)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på SJG-136
-
National Cancer Institute (NCI)AvslutadÅterkommande akut myeloid leukemi hos vuxna | Akut myeloid leukemi hos vuxna med 11q23 (MLL) avvikelser | Vuxen akut myeloid leukemi med Inv(16)(p13;q22) | Akut myeloid leukemi hos vuxna med t(16;16)(p13;q22) | Akut myeloid leukemi hos vuxna med t(8;21)(q22;q22) | Sekundär akut myeloid leukemi | Tidigare... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)AvslutadOspecificerad fast tumör för vuxen, protokollspecifikFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande epitelial cancer i äggstockarna | Återkommande primär peritonealcancer | Återkommande äggledarcancerFörenta staterna
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutad
-
Centocor Research & Development, Inc.AvslutadLupus erythematosus, systemisk | Lupus erythematosus, kutan
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutad
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutad
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutad
-
NeuShen TherapeuticsRekrytering
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutad